Skip to main content

Article Filters

Astrea Bioseparations joins Biotage, enabling groundbreaking chromatography solutions

Published date: 01 June 2023

Back to Article Listing

Kieran Murphy and Kugan Sathiyanandarajah become members of the Biotage board of directors

 
Uppsala, Sweden – 1 June 2023 – Biotage has completed the acquisition of Astrea Bioseparations, a high-growth chromatography solutions provider from Gamma Biosciences, a life sciences tools platform created by KKR.

Astrea’s over 150 employees worldwide will join Biotage, and the company’s production sites in Cambridge, UK, Isle of Man, Boston, USA, and Joliette, Canada become an important part of Biotage’s global presence.

Biotage’s expanded portfolio will now include chromatography resins, absorbents, and columns as well as nanofiber-based purification technologies, serving biologics and advanced therapeutic customers. This complements the company’s existing purification solutions predominantly targeting small molecules and synthetic therapeutics.

Tomas Blomquist, CEO and President at Biotage, said: “The acquisition of Astrea Bioseparations allows us to build a transformative platform company within chromatography targeting both small and large molecules. With Astrea’s expert team and broad product portfolio with a near-term pipeline of product launches we are now well-equipped to target biologics and the new modalities emerging in the biopharma industry.

Terry Pizzie, CEO, Astrea Bioseparations, said: “Joining forces with Biotage marks an exciting chapter for Astrea Bioseparations. By combining the expertise of our teams alongside our innovative product offerings, we are well-positioned to drive novel breakthroughs in the chromatography sector. Together, we can provide comprehensive solutions to meet the evolving needs of the biopharma industry, particularly in the realm of biologics and advanced therapeutics. This collaboration opens up new avenues for growth and underscores our commitment to delivering exceptional chromatography solutions.

Kieran Murphy and Kugan Sathiyanandarajah become new members of the Biotage board of directors. The appointments were approved at the Biotage annual general meeting held on 27 April 2023 and they were conditional upon the completion of the Astrea Bioseparations transaction.

Read here the full regulatory release on the acquisition

About Biotage

Biotage is a Global Impact Tech Company committed to solving society’s problems by offering solutions and products to customers in drug discovery and development and diagnostics, analytical testing and water and environmental testing.

Our customers span a broad range of market segments including pharmaceutical, biotech, diagnostic, contract research and contract manufacturers as well as clinical, forensic, and academic laboratories in addition to organizations focused on food safety, clean water and environmental sustainability.

Biotage is headquartered in Uppsala in Sweden and employs over 500 people worldwide and our products are sold in more than 80 countries. Biotage’s share (BIOT) is listed in the Large Cap segment on the NASDAQ Stockholm. www.biotage.com

About Astrea Bioseparations

Astrea Bioseparations is a leading provider of chromatography solutions for the life sciences industry. With products used in the manufacture of over 20 approved therapeutic and medical products, Astrea is trusted by scientists around the world to deliver precise, reliable results. Astrea Bio is headquartered in Cambridge, UK with manufacturing facilities at the Isle of Man, British Isles, Joliette, Quebec and Massachusett, USA. www.astreabioseparations.com

FOR FURTHER INFORMATION PLEASE CONTACT:

Hannah Ingram
Head of Marketing
h.ingram@astrea-bio.com
+44 (0)1223 736 983

Your basket

Your basket is empty. Continue shopping to add products to your basket.

Search our catalogue

Call Centre

Request Quote

Please enter a valid Email AddressPlease enter a valid Email AddressThe Email Address entered is already registered, please sign in with the Email Address or enter a different one

Please enter your NamePlease enter a valid Name, the maximum length is 65 characters.

Please enter a Contact NumberPlease enter a valid Contact Number, the maximum length is 30 characters.

Please enter your company name

Please enter the quantity of products you want a quote for

Please enter the date you need these products byPlease enter a date in the format DD/MM/YYYY

Astrea Bioseparations joins Biotage, enabling groundbreaking chromatography solutions

Published date: 01 June 2023

Back to Article Listing

Kieran Murphy and Kugan Sathiyanandarajah become members of the Biotage board of directors

 
Uppsala, Sweden – 1 June 2023 – Biotage has completed the acquisition of Astrea Bioseparations, a high-growth chromatography solutions provider from Gamma Biosciences, a life sciences tools platform created by KKR.

Astrea’s over 150 employees worldwide will join Biotage, and the company’s production sites in Cambridge, UK, Isle of Man, Boston, USA, and Joliette, Canada become an important part of Biotage’s global presence.

Biotage’s expanded portfolio will now include chromatography resins, absorbents, and columns as well as nanofiber-based purification technologies, serving biologics and advanced therapeutic customers. This complements the company’s existing purification solutions predominantly targeting small molecules and synthetic therapeutics.

Tomas Blomquist, CEO and President at Biotage, said: “The acquisition of Astrea Bioseparations allows us to build a transformative platform company within chromatography targeting both small and large molecules. With Astrea’s expert team and broad product portfolio with a near-term pipeline of product launches we are now well-equipped to target biologics and the new modalities emerging in the biopharma industry.

Terry Pizzie, CEO, Astrea Bioseparations, said: “Joining forces with Biotage marks an exciting chapter for Astrea Bioseparations. By combining the expertise of our teams alongside our innovative product offerings, we are well-positioned to drive novel breakthroughs in the chromatography sector. Together, we can provide comprehensive solutions to meet the evolving needs of the biopharma industry, particularly in the realm of biologics and advanced therapeutics. This collaboration opens up new avenues for growth and underscores our commitment to delivering exceptional chromatography solutions.

Kieran Murphy and Kugan Sathiyanandarajah become new members of the Biotage board of directors. The appointments were approved at the Biotage annual general meeting held on 27 April 2023 and they were conditional upon the completion of the Astrea Bioseparations transaction.

Read here the full regulatory release on the acquisition

About Biotage

Biotage is a Global Impact Tech Company committed to solving society’s problems by offering solutions and products to customers in drug discovery and development and diagnostics, analytical testing and water and environmental testing.

Our customers span a broad range of market segments including pharmaceutical, biotech, diagnostic, contract research and contract manufacturers as well as clinical, forensic, and academic laboratories in addition to organizations focused on food safety, clean water and environmental sustainability.

Biotage is headquartered in Uppsala in Sweden and employs over 500 people worldwide and our products are sold in more than 80 countries. Biotage’s share (BIOT) is listed in the Large Cap segment on the NASDAQ Stockholm. www.biotage.com

About Astrea Bioseparations

Astrea Bioseparations is a leading provider of chromatography solutions for the life sciences industry. With products used in the manufacture of over 20 approved therapeutic and medical products, Astrea is trusted by scientists around the world to deliver precise, reliable results. Astrea Bio is headquartered in Cambridge, UK with manufacturing facilities at the Isle of Man, British Isles, Joliette, Quebec and Massachusett, USA. www.astreabioseparations.com

FOR FURTHER INFORMATION PLEASE CONTACT:

Hannah Ingram
Head of Marketing
h.ingram@astrea-bio.com
+44 (0)1223 736 983

Call Centre Product Compare